| 4.24 0.66 (18.44%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.57 | 1-year : | 8.46 |
| Resists | First : | 5.62 | Second : | 7.25 |
| Pivot price | 4.05  |
|||
| Supports | First : | 3 | Second : | 2.49 |
| MAs | MA(5) : | 3.83 |
MA(20) : | 4.4 |
| MA(100) : | 6.75 |
MA(250) : | 15.77 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 22.7 |
D(3) : | 15.8 |
| RSI | RSI(14): 49.3 |
|||
| 52-week | High : | 41.59 | Low : | 3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NXGL ] has closed below upper band by 39.4%. Bollinger Bands are 43% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.3 - 4.32 | 4.32 - 4.34 |
| Low: | 3.58 - 3.6 | 3.6 - 3.62 |
| Close: | 4.2 - 4.24 | 4.24 - 4.27 |
NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology. NEXGEL's diverse product range serves crucial applications across several sectors, including wound care management, medical diagnostic tools, transdermal drug delivery systems, and cosmetic formulations. The company was founded in 1997 and operated under the name AquaMed Technologies, Inc. until it rebranded as NEXGEL, Inc. in November 2019. Its headquarters are located in Langhorne, Pennsylvania.
Fri, 06 Nov 2026
NEXGEL, Inc. (NXGL) Seasonal returns chart - Yahoo Finance UK
Tue, 03 Nov 2026
NEXGEL, Inc. (NXGL) Seasonal returns chart - Yahoo Finance - Yahoo Finance Singapore
Mon, 12 Oct 2026
NEXGEL Announces 1-for-20 Reverse Stock Split and Split-Adjusted Trading on Nasdaq Capital Market - Quiver Quantitative
Wed, 30 Sep 2026
An affiliate proposes selling 227,956 Nexgel (Nasdaq: NXGL) shares, valued at about $41.2K. - Stock Titan
Wed, 23 Sep 2026
NEXGEL Announces Dial-In Details for Investor Update Call - GlobeNewswire
Thu, 20 Aug 2026
NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 14 (%) |
| Held by Institutions | 13.7 (%) |
| Shares Short | 105 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -14.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.19 |
| Profit Margin | -51.3 % |
| Operating Margin | -68 % |
| Return on Assets (ttm) | -18.7 % |
| Return on Equity (ttm) | -115.1 % |
| Qtrly Rev. Growth | 27.7 % |
| Gross Profit (p.s.) | 8.67 |
| Sales Per Share | 24.76 |
| EBITDA (p.s.) | -8.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 8 (M) |
| PE Ratio | -0.29 |
| PEG Ratio | 0 |
| Price to Book value | 0.41 |
| Price to Sales | 0.17 |
| Price to Cash Flow | -0.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|